The estimated Net Worth of Gregory Paul Winter is at least $4.46 Milhão dollars as of 14 April 2020. Sir Winter owns over 71,450 units of Bicycle Therapeutics plc stock worth over $4,419,472 and over the last 5 years he sold BCYC stock worth over $0. In addition, he makes $40,000 as Co-Founder e Non-Exec. Director & Member of Scientific Advisory Board at Bicycle Therapeutics plc.
Sir has made over 1 trades of the Bicycle Therapeutics plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 71,450 units of BCYC stock worth $1,926,292 on 14 April 2020.
The largest trade he's ever made was exercising 71,450 units of Bicycle Therapeutics plc stock on 14 April 2020 worth over $1,926,292. On average, Sir trades about 10,207 units every 0 days since 2019. As of 14 April 2020 he still owns at least 163,927 units of Bicycle Therapeutics plc stock.
You can see the complete history of Sir Winter stock trades at the bottom of the page.
Sir Gregory Paul Winter is the Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board at Bicycle Therapeutics plc.
As the Co-Founder e Non-Exec. Director & Member of Scientific Advisory Board of Bicycle Therapeutics plc, the total compensation of Sir Winter at Bicycle Therapeutics plc is $40,000. There are 8 executives at Bicycle Therapeutics plc getting paid more, with Dr. Kevin Lee M.B.A., Ph.D. having the highest compensation of $1,156,784.
Sir Winter is 69, he's been the Co-Founder e Non-Exec. Director & Member of Scientific Advisory Board of Bicycle Therapeutics plc since . There are 1 older and 10 younger executives at Bicycle Therapeutics plc. The oldest executive at Bicycle Therapeutics plc is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, 70, who is the Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board.
Gregory's mailing address filed with the SEC is C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0, CB21 6GS.
Over the last 5 years, insiders at Bicycle Therapeutics plc have traded over $10,024,476 worth of Bicycle Therapeutics plc stock and bought 3,275,775 units worth $45,860,850 . The most active insiders traders include Plc Gsk, Bros. Advisors Lp667, L.P.B..., eBioventures Ltd Novartis Ag.... On average, Bicycle Therapeutics plc executives and independent directors trade stock every 19 days with the average trade being worth of $1,155,236. The most recent stock trade was executed by Michael Charles Ferguson Ha... on 3 July 2024, trading 246 units of BCYC stock currently worth $4,831.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics plc executives and other stock owners filed with the SEC include: